Drug - including opioid - dependence is common in correctional populations, however little research exists on interventions for women offenders. Based on retrospective administrative data, we examined rates of return to custody (RTC) among three samples of Canadian federal women offenders with problematic opioid use (total n = 137): (1) a group initiated on MMT during incarceration who continued MMT post-release (MMT-C; n = 25); (2) a group initiated on MMT but who terminated treatment post-release (MMT-T; n = 67), and (3) a non-MMT control group (MMT-N; n = 45). Study groups were similar regarding socio-demographic, drug use and criminogenic indicators. Based on an unadjusted Cox proportional hazards model, the MMT-C group had a 65% lower risk of RTC than the MMT-N (reference) group (HR 0.35, CI 0.13-0.90); RTC risk was not different between the MMT-T and the reference group. Most RTCs were for technical revocations (e.g. violation of a legal condition of their release). Continuous MMT following release from corrections appears to be effective in reducing recidivism in women offenders with opioid problems; barriers to MMT in the study population should be better understood and ameliorated.

1.
Fazel S, Bains P, Doll H: Substance abuse and dependence in prisoners: a systematic review. Addiction 2006;101:181-191.
2.
Henderson DJ: Drug abuse and incarcerated women: a research review. J Subst Abuse Treat 1998;15:579-587.
3.
Matheson FI, Doherty S, Grant BA: Community-based after care and return to custody in a national sample of substance-abusing women offenders. Am J Public Health 2011;101:1126-1132.
4.
Plugge E, Yudkin P, Douglas N: Changes in women's use of illicit drugs following imprisonment. Addiction 2009;104:215-222.
5.
Grant BA, Gileno J: The Changing Federal Offender Population. Ottawa, Correctional Service of Canada, 2008.
6.
Zakaria D, Thompson J, Jarvis A, Borgatta F: Summary of emerging findings from the 2007 National Inmate Infectious Disease and Risk-Behaviours Survey. Ottawa, Correctional Service of Canada, 2010.
7.
Calzavara L, Burchell A, Schlossberg J, Myers T, Escobar M, Wallace E, Major C, Strike C, Millson M: Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction 2003;98:1257-1265.
8.
Strang J, Gossop M, Heuston J, Green J, Whiteley C, Maden A: Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. Addiction 2006;101:1125-1132.
9.
Amari E, Rehm J, Goldner E, Fischer B: Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review. Can J Psychiatry 2011;56:495-502.
10.
Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D: The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318-1327.
11.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-171.
12.
Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noël L, Tyndall M, Wild C, Mun P, Baliunas D: Illicit opioid use in Canada: comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82:250-266.
13.
Marsch LA: The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998;93:515-532.
14.
Nicholls L, Bragaw L, Ruetsch C: Opioid dependence treatment and guidelines. J Manag Care Pharm 2010;16(suppl B):S14-S21.
15.
World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, WHO, 2009.
16.
Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;3:CD002209.
17.
Ward J, Hall W, Mattick R: Role of maintenance treatment in opioid dependence. Lancet 1999;353:221-226.
18.
Larney S, Dolan K: A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res 2009;15:107-112.
19.
Dolan K, Shearer J, White B, Zhou J, Kaldor J, Wodak AD: Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820-828.
20.
Dolan K, Wodak A, Hall W: Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev 1998;17:153-158.
21.
Johnson S, van de Ven JTC, Grant BA: Institutional methadone maintenance treatment: impact on release outcome and institutional behaviour. Ottawa, Correctional Service Canada, 2001.
22.
Larney S, Toson B, Burns L, Dolan K: Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction 2012;107:372-380.
23.
Motiuk L, Dowden C, Nafekh M: Methadone Maintenance Treatment (MMT) Programming for Federal Prisoners: A Preliminary Investigation. Ottawa, Correctional Service of Canada, 1999.
24.
Jones HE, Fitzgerald H, Johnson RE: Males and females differ in response to opioid agonist medications. Am J Addict 2005;14:223-233.
25.
Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, Nosyk B, Krausz M, Anis A, Schechter MT: Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend 2010;111:50-57.
26.
Messina N, Grella CE, Cartier J, Torres S: A randomized experimental study of gender-responsive substance abuse treatment for women in prison. J Subst Abuse Treat 2010;38:97-107.
27.
Pelissier BMM, Camp SD, Gaes GG, Saylor WG, Rhodes W: Gender differences in outcomes from prison-based residential treatment. J Subst Abuse Treat 2003;24:149-160.
28.
Cropsey KL, Lane PS, Hale GJ, Jackson DO, Clark B, Ingersoll KS, Islam MA, Stitzer ML: Results of a pilot randomized controlled trial of buprenorphine for opioid-dependent women in the criminal justice system. Drug Alcohol Depend 2011;119:172-178.
29.
Grella CE, Stein JA, Greenwell L: Associations among childhood trauma, adolescent problem behaviors, and adverse adult outcomes in substance-abusing women offenders. Psychol Addict Behav 2005;19:43-53.
30.
Messina N, Burdon W, Hagopian G, Prendergast M: Predictors of prison-based treatment outcomes: a comparison of men and women participants. Am J Drug Alcohol Abuse 2006;32:7-28.
31.
Peters RH, Strozier AL, Murrin MR, Kearns WD: Treatment of substance-abusing jail inmates: examination of gender differences. J Subst Abuse Treat 1997;14:339-349.
32.
Zlotnick C, Clarke JG, Friedmann PD, Roberts MB, Sacks S, Melnick G: Gender differences in comorbid disorders among offenders in prison substance abuse treatment programs. Behav Sci Law 2008;26:403-412.
33.
Langan NP, Pelissier BM: Gender differences among prisoners in drug treatment. J Subst Abuse 2001;13:291-301.
34.
Stover H, Casselman J, Hennebel L: Substitution treatment in European prisons: a study of policies and practices in 18 European countries. Int J Prison Health 2006;2:3-12.
35.
Oser C, Knudsen H, Staton-Tindall M, Leukefeld C: The adoption of wraparound services among substance abuse treatment organizations serving criminal offenders: the role of a women-specific program. Drug Alcohol Depend 2009;103(suppl 1):S82-S90.
36.
Sibbald B: Methadone maintenance expands inside federal prisons. CMAJ 2002;167:1154.
37.
MacSwain M, Cheverie M, Farrell MacDonald S, Johnson S: Characteristics of Women Participants in the Methadone Maintenance Treatment (MMT) Program. Ottawa, Correctional Service of Canada, 2012.
38.
Johnson S, Farrell MacDonald S, Cheverie M: Characteristics of Participants in the Methadone Maintenance Treatment (MMT) Program. Ottawa, Correctional Service Canada, 2011.
39.
Dohoo I, Martin W, Stryhn H: Veterinary Epidemiologic Research, ed 2. Charlottetown/PE, VER Inc, 2009.
40.
Gobeil R, Barrett M: Rates of Recidivism for Women Offenders. Ottawa, Correctional Service Canada, 2008.
41.
Matheson FI, Doherty S, Grant BA: Women Offender Substance Abuse Programming and Community Reintegration. Ottawa, Correctional Service Canada, 2008.
42.
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321-329.
43.
Pearson FS, Lipton DS: A meta-analytic review of the effectiveness of corrections-based treatments for drug abuse. Prison J 1999;79:384-410.
44.
Magura S, Rosenblum A, Lewis C, Joseph H: The effectiveness of in-jail methadone maintenance. J Drug Issues 1993;23:75-99.
45.
Butzin CA, Martin SS, Inciardi JA: Evaluating component effects of a prison-based treatment continuum. J Subst Abuse Treat 2002;22:63-69.
46.
Messina N, Burdon W, Prendergast M: Prison-based treatment for drug-dependent women offenders: treatment versus no treatment. J Psychoactive Drugs 2006;(suppl 3):333-343.
47.
Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, Mokri A: Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Subst Abuse Rehabil 2012;3(suppl 1):37-43.
48.
Notley C, Blyth A, Maskrey V, Craig J, Holland R: The experience of long-term opiate maintenance treatment and reported barriers to recovery: a qualitative systematic review. Eur Addict Res 2013;19:287-298.
49.
Barrett M, Allenby K, Taylor K: Twenty Years Later: Revisiting the Task Force on Federally Sentenced Women. Ottawa, Correctional Service Canada, 2010.
50.
Chandler RK, Fletcher BW, Volkow ND: Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009;301:183-190.
51.
Marzo JN, Rotily M, Meroueh F, Varastet M, Hunault C, Obradovic I, Zin A: Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-2006). Addiction 2009;104:1233-1240.
52.
Prendergast ML: Interventions to promote successful re-entry among drug-abusing parolees. Addict Sci Clin Pract 2009;5:4-13.
53.
Rich JD, Holmes L, Salas C, Macalino G, Davis D, Ryczek J, Flanigan T: Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health 2001;78:279-289.
54.
McMillan GP, Lapham S, Lackey M: The effect of a jail methadone maintenance therapy (MMT) program on inmate recidivism. Addiction 2008;103:2017-2023.
55.
Lind B, Chen S, Weatherburn D, Mattick R: The effectiveness of methadone maintenance treatment in controlling crime: an Australian aggregate-level analysis. Br J Criminol 2005;45:201-211.
56.
Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N: The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction 2010;105:732-739.
57.
Zhang Z, Friedmann PD, Gerstein DR: Does retention matter? Treatment duration and improvement in drug use. Addiction 2003;98:673-684.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.